FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891594457> ?p ?o ?g. }

• W2891594457 endingPage "5360" @default.
• W2891594457 startingPage "5349" @default.
• W2891594457 abstract "Simvastatin is one of the most widely used active pharmaceutical ingredients for the treatment of hyperlipidemias. Because the compound is employed as a solid in drug formulations, particular attention should be given to the characterization of different polymorphs, their stability domains, and the nature of the phase transitions that relate them. In this work, the phase transitions delimiting the stability domains of three previously reported simvastatin forms were investigated from structural, energetics, and dynamical points of view based on single crystal X-ray diffraction (SCXRD), hot stage microscopy (HSM), and differential scanning calorimetry (DSC) experiments (conventional scans and heat capacity measurements), complemented with molecular dynamics (MD) simulations. Previous assignments of the crystal forms were confirmed by SCXRD: forms I and II were found to be orthorhombic ( P212121, Z'/ Z = 1/4) and form III was monoclinic ( P21, Z'/ Z = 2/4). The obtained results further indicated that (i) the transitions between different forms are observed at 235.9 ± 0.1 K (form III → form II) and at 275.2 ± 0.2 K (form II → form I) in DSC runs carried out at 10 K min-1 and close to these values when other types of techniques are used (e.g., HSM). (ii) They are enantiotropic (i.e., there is a transition temperature relating the two phases before fusion at which the stability order is reversed), fast, reversible, with very little hysteresis between heating and cooling modes, and occur under single crystal to single crystal conditions. (iii) A nucleation and growth mechanism seems to be followed since HSM experiments on single crystals evidenced the propagation of an interface, accompanied by a change of birefringence and crystal contraction or expansion (more subtle in the case of form III → form II), when the phase transitions are triggered. (iv) Consistent with the reversible and small hysteresis nature of the phase transitions, the SCXRD results indicated that the molecular packing is very similar in all forms and the main structural differences are associated with conformational changes of the ester tail. (v) The MD simulations further suggested that the tail is essentially frozen in two conformations below the III → II transition temperature, becomes progressively less hindered throughout the stability domain of form II, and acquires a large conformational freedom above the II → I transition. Finally, the fact that these transitions were found to be fast and reversible suggests that polymorphism is unlikely to be a problem for pharmaceutical formulations employing crystalline simvastatin because, if present, the III and II forms will readily convert to form I at ambient temperature." @default.
• W2891594457 created "2018-09-27" @default.
• W2891594457 creator A5004351773 @default.
• W2891594457 creator A5009243666 @default.
• W2891594457 creator A5048636019 @default.
• W2891594457 creator A5049934091 @default.
• W2891594457 creator A5063196954 @default.
• W2891594457 creator A5078743768 @default.
• W2891594457 creator A5083577883 @default.
• W2891594457 date "2018-09-19" @default.
• W2891594457 modified "2023-10-17" @default.
• W2891594457 title "Polymorphism in Simvastatin: Twinning, Disorder, and Enantiotropic Phase Transitions" @default.
• W2891594457 cites W1031578623 @default.
• W2891594457 cites W1967086749 @default.
• W2891594457 cites W1979368277 @default.
• W2891594457 cites W2006128404 @default.
• W2891594457 cites W2010474851 @default.
• W2891594457 cites W2012154384 @default.
• W2891594457 cites W2017020876 @default.
• W2891594457 cites W2024106850 @default.
• W2891594457 cites W2051381895 @default.
• W2891594457 cites W2063334178 @default.
• W2891594457 cites W2064468313 @default.
• W2891594457 cites W2083597234 @default.
• W2891594457 cites W2106765253 @default.
• W2891594457 cites W2131350133 @default.
• W2891594457 cites W2304702132 @default.
• W2891594457 cites W2313111263 @default.
• W2891594457 cites W2315527902 @default.
• W2891594457 cites W2316797976 @default.
• W2891594457 cites W2319902168 @default.
• W2891594457 cites W2323149066 @default.
• W2891594457 cites W2324966884 @default.
• W2891594457 cites W2326939007 @default.
• W2891594457 cites W2506880365 @default.
• W2891594457 cites W2577631083 @default.
• W2891594457 cites W3101910729 @default.
• W2891594457 cites W4241671505 @default.
• W2891594457 cites W4248515682 @default.
• W2891594457 cites W4292329040 @default.
• W2891594457 doi "https://doi.org/10.1021/acs.molpharmaceut.8b00818" @default.
• W2891594457 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30230340" @default.
• W2891594457 hasPublicationYear "2018" @default.
• W2891594457 type Work @default.
• W2891594457 sameAs 2891594457 @default.
• W2891594457 citedByCount "17" @default.
• W2891594457 countsByYear W28915944572019 @default.
• W2891594457 countsByYear W28915944572020 @default.
• W2891594457 countsByYear W28915944572021 @default.
• W2891594457 countsByYear W28915944572022 @default.
• W2891594457 countsByYear W28915944572023 @default.
• W2891594457 crossrefType "journal-article" @default.
• W2891594457 hasAuthorship W2891594457A5004351773 @default.
• W2891594457 hasAuthorship W2891594457A5009243666 @default.
• W2891594457 hasAuthorship W2891594457A5048636019 @default.
• W2891594457 hasAuthorship W2891594457A5049934091 @default.
• W2891594457 hasAuthorship W2891594457A5063196954 @default.
• W2891594457 hasAuthorship W2891594457A5078743768 @default.
• W2891594457 hasAuthorship W2891594457A5083577883 @default.
• W2891594457 hasConcept C104317684 @default.
• W2891594457 hasConcept C115624301 @default.
• W2891594457 hasConcept C121332964 @default.
• W2891594457 hasConcept C135763542 @default.
• W2891594457 hasConcept C149288129 @default.
• W2891594457 hasConcept C149737253 @default.
• W2891594457 hasConcept C178790620 @default.
• W2891594457 hasConcept C185592680 @default.
• W2891594457 hasConcept C192562407 @default.
• W2891594457 hasConcept C37243968 @default.
• W2891594457 hasConcept C39519442 @default.
• W2891594457 hasConcept C55493867 @default.
• W2891594457 hasConcept C61048295 @default.
• W2891594457 hasConcept C61276311 @default.
• W2891594457 hasConcept C6840138 @default.
• W2891594457 hasConcept C73922627 @default.
• W2891594457 hasConcept C8010536 @default.
• W2891594457 hasConcept C87976508 @default.
• W2891594457 hasConcept C97355855 @default.
• W2891594457 hasConceptScore W2891594457C104317684 @default.
• W2891594457 hasConceptScore W2891594457C115624301 @default.
• W2891594457 hasConceptScore W2891594457C121332964 @default.
• W2891594457 hasConceptScore W2891594457C135763542 @default.
• W2891594457 hasConceptScore W2891594457C149288129 @default.
• W2891594457 hasConceptScore W2891594457C149737253 @default.
• W2891594457 hasConceptScore W2891594457C178790620 @default.
• W2891594457 hasConceptScore W2891594457C185592680 @default.
• W2891594457 hasConceptScore W2891594457C192562407 @default.
• W2891594457 hasConceptScore W2891594457C37243968 @default.
• W2891594457 hasConceptScore W2891594457C39519442 @default.
• W2891594457 hasConceptScore W2891594457C55493867 @default.
• W2891594457 hasConceptScore W2891594457C61048295 @default.
• W2891594457 hasConceptScore W2891594457C61276311 @default.
• W2891594457 hasConceptScore W2891594457C6840138 @default.
• W2891594457 hasConceptScore W2891594457C73922627 @default.
• W2891594457 hasConceptScore W2891594457C8010536 @default.
• W2891594457 hasConceptScore W2891594457C87976508 @default.
• W2891594457 hasConceptScore W2891594457C97355855 @default.
• W2891594457 hasFunder F4320320366 @default.

• next